January 23, 2026- Abbott announced financial results for the fourth quarter ended Dec. 31, 2025.
- Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales.
- Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent.
- Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales.
- Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent.
- Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
- Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.
- In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market. Abbott continues to expect the transaction to close in the second quarter of 2026.
- Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:
- In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System, bringing Abbott’s first pulsed field ablation (PFA) offering to patients in the United States.
- In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.
Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%. Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18.
Continue Reading from Abbott.